Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : IPA-3
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : MetasTx
Deal Size : Undisclosed
Deal Type : Partnership
Details : The stability and efficacy of MTX-101 (IPA-3), are significantly superior in inhibiting prostate tumor growth and metastasis in various mouse models of prostate cancer and demonstrate broad applicability across solid tumor cancers.
Brand Name : MTX-101
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 07, 2022
Lead Product(s) : IPA-3
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : MetasTx
Deal Size : Undisclosed
Deal Type : Partnership
LOOKING FOR A SUPPLIER?